Pretibial myxedema is a condition in which there is loeal thickening of the skin by a mucin-like deposit; it is nearly always asosciated with ophthalmopathy and thyrotoxicosis, not infrequently becomes more pronounced after treatrnent of thyrotoxicosis. The precise cause of pretibial myxedema is not known, but it appears that IgG LATS represents an autoantibody against a thyroid antigen, retroorbital tiesue and tbe skin, so, pretibial myxedema is presumed to be the result of a local antigen-antibody tissue reaction. A 57-year-old man had the history of diabetes since 1964 and Graves disease since May 1980, he was treated with metimazole for 1 month, with improving thyrotoxicosis but developed the pretibial myxedema. The histologic findings showed considerable amount of mucin, especially hyaluronic acid with toluidin blue stain at PH 3.0. The lesions were improved by local application of 0.01 x fluocinolone acetonide ointment with occlusive dressing technique.
Fluocinolone Acetonide ; Graves Disease ; Humans ; Hyaluronic Acid ; Hydrogen-Ion Concentration ; Immunoglobulin G ; Long-Acting Thyroid Stimulator ; Middle Aged ; Mucins ; Myxedema* ; Occlusive Dressings ; Skin ; Thyroid Gland ; Thyrotoxicosis

PURPOSE: Recurrent respiratory tract infection is a common manifestation of primary immunodeficiency disease, and respiratory viruses or bacteria are important triggers of asthma exacerbations. Asthma often coexists with humoral immunodeficiency in adults, and some asthmatics with immunoglobulin (Ig) G subclass deficiency (IgGSCD) suffer from recurrent exacerbations. Although some studies suggest a benefit from Ig replacement, others have failed to support its use. This study aimed to assess the effect of Ig replacement on asthma exacerbation caused by respiratory infection as well as the asthma control status of adult asthmatics with IgGSCD. METHODS: This is a multi-center, open-label study of adult asthmatics with IgGSCD. All patients received monthly intravenous immunoglobulin (IVIG) for 6 months and were evaluated regarding asthma exacerbation related to infection, asthma control status, quality of life, and lung function before and after IVIG infusion. RESULTS: A total of 30 patients were enrolled, and 24 completed the study. Most of the patients had a moderate degree of asthma severity with partly (52%) or uncontrolled (41%) status at baseline. IVIG significantly reduced the proportion of patients with asthma exacerbations, lowered the number of respiratory infections, and improved asthma control status, compared to the baseline values (P<0.001). The mean asthma-specific quality of life and asthma control test scores were improved significantly (P=0.009 and P=0.053, respectively); however, there were no significant changes in lung function. CONCLUSIONS: IVIG reduced the frequency of asthma exacerbations and improved asthma control status in adult asthmatics with IgGSCD, suggesting that IVIG could be an effective treatment option in this population.
Adult* ; Asthma* ; Bacteria ; Humans ; Immunoglobulin G* ; Immunoglobulins* ; Immunoglobulins, Intravenous ; Lung ; Quality of Life ; Respiratory Tract Infections

Common clinical manifestations in patients with IgG subclass deficiency include recurrent respiratory tract infection, recurrent otitis media and sinopulmonary infection by virus or bacteria. The administration of intravenous immunoglobulin (IVIG) has been regarded as the most effective therapy in these patients. We experienced a 22-year-old patient with IgG3 subclass deficiency and recurrent fungal infection of oral cavity and lips. IVIG was given at 0.2g/kg/dose twice a month for 6 months. After treatment with IVIG, the patient improved clinically.
Bacteria ; Humans ; Immunoglobulin G* ; Immunoglobulins ; Immunoglobulins, Intravenous ; Lip ; Mouth* ; Otitis Media ; Respiratory Tract Infections ; Young Adult

No abstract available.
Immunoglobulin G ; Psoriasis ; Receptors, Tumor Necrosis Factor ; Etanercept

No abstract available.
Immunoglobulin G*

No abstract available.
Immunoglobulin G*

No abstract available.
Immunoglobulin G

OBJECTIVETo detect desialylation of platelets in primary immune thrombocytopenia(ITP) patients with FITC-labelled ECL and RCA-1, and compare the correlation of the desialylation level and the efficacy of first-line therapy for ITP.

METHODSBefore treatment, 48 ITP patients were selected and their levels of ECL and RCA-1 were detected with flow cytometry.

RESULTSThe desialylation level in the different efficacy groups by using the first-line therapy of corticosteroids and (or) intravenous immunoglobulin G (IVIG) had a statistically significant difference (P<0.05). The correlation analysis showed negative relation of the therapeutic efficacy with desialylation level, that is to say, the more high of desialylation level, the more poor therapeutic efficacy of the first-line therapy.

CONCLUSIONThe desialylation level of platelets in ITP patients is related with the first-line therapeutic efficacy, the efficacy for patients with high desialylation level is poor, suggesting that the FcR-independent pathway exists in clearance of platelets in ITP patients. Therefore, the desialylation level of platelets may suggest the first-line therapeutic efficacy for ITP patients to a certain degree, and may be used as a potential target for the treatment of refractory ITP.

PURPOSE: Premature infants have low serum immunoglobulin G (IgG) levels because IgG is transplacentally acquired, primarily after 32-34 weeks of gestational age. We studied the transplacental transfer of serum IgG in preterm infants. METHODS: The IgG levels in the sera were measured by radial immunodiffusion method (Behring nephelometer, Germany). RESULTS: There was a significant difference between IgG concentration and gestational age; the IgG concentration increased from 462.2 +/- 105.5mg/dL at less than 26 weeks of gestation to 1009.0 +/- 242.6mg/dL at 35 and 36 weeks of gestation with increasing gestational age (P<0.01). The linear relation between IgG concentration and birthweight; the IgG concentration in the sera of premature infants were increased from 588.3 +/- 136.4mg/dL at birthweight less than 1250g to 1149.3 +/- 287.8mg/dL at birthweight more than 2251g with increasing birth weight (P<0.05). CONCLUSION: The effects of gestational age and birthweight on the concentration of IgG at birth were highly interdependent and significant. These results suggest that IVIG administration is needed for nearly all premature infants with birthweight less than 1200g and gestational age less than 32 weeks.
Birth Weight ; Gestational Age ; Humans ; Immunodiffusion ; Immunoglobulin G* ; Immunoglobulins* ; Immunoglobulins, Intravenous ; Infant, Newborn ; Infant, Premature* ; Parturition ; Pregnancy

BACKGROUND: Immune thrombocytopenic purpura (ITP) is a frequently observed bleeding disorder in children. High dose intravenous immunoglobulin G (IVIG) has been used for the treatment of ITP since 1981, and now several methods of IVIG infusion are used. Since 1983, we have treated ITP patients with short-term and low-dose IVIG according to the individual patient's daily response. This study aimed to evaluate individual patient's response after IVIG for the prediction of chronic ITP.METHODS: We evaluated 259 childhood ITP patients retrospectively who were newly diagnosed at the Department of Pediatrics, Kyungpook National University Hospital from 1983 to 2012. We analyzed the individual response to treatment and current state of disease. We evaluated the time to reach desired platelet counts after treatment of IVIG, relapse rate and diagnosis of chronic ITP. The patients were classified into 2 groups according to the time to reach desired platelet counts (50,000/microL) after daily treatment of IVIG, rapid (1 or 2 doses) and slow responder (more than 3 doses).RESULTS: Among 182 patients followed up over 6 months, 41 patients (22.5%) were eventually diagnosed with chronic ITP. Hundred and two patients (56.7%) belonged to rapid response group, and 17 of them (16.7%) were diagnosed with chronic ITP. Eighty patients (44.4%) belonged to the slow response group, and 24 of them (30%) were diagnosed with chronic ITP, which were higher than the early response group (P=0.033).CONCLUSION: Individual response rate of IVIG treatment could be a useful predictor of chronic ITP, but this finding needs support from further studies.
Child ; Diagnosis ; Hemorrhage ; Humans ; Immunoglobulin G ; Immunoglobulins ; Immunoglobulins, Intravenous ; Methods ; Pediatrics ; Platelet Count ; Purpura, Thrombocytopenic, Idiopathic ; Recurrence ; Retrospective Studies